By: IPP Bureau
Last updated : July 30, 2026 9:05 am
With an eye on USD 413 million market, the company plans to launch the product in the coming days in partnership with Hypera Pharma, one of Brazil's leading pharmaceutical companies
Sun Pharmaceutical Industries Ltd. has received approval from Brazil's health regulator, ANVISA, to manufacture and market semaglutide injection for the treatment of adults with inadequately controlled type 2 diabetes mellitus, to be used alongside diet and exercise.
The company plans to launch the product in the coming days in partnership with Hypera Pharma, one of Brazil's leading pharmaceutical companies.
The therapy will be available as a prefilled, multidose injectable pen in two strengths—2 mg/1.5 mL and 4 mg/3 mL—supporting flexible once-weekly dosing.
“The approval of semaglutide in Brazil expands access to an evidence-based treatment option for people living with inadequately controlled type 2 diabetes. It reflects the strength of our development and manufacturing capabilities and our commitment to delivering high-quality medicines across global markets,” said Aalok Shanghvi, Chief Operating Officer, Sun Pharma.
Digvijay Singh, Regional Head, Brazil & LATAM, said, “This approval marks an important step in strengthening our diabetes portfolio in Brazil. We look forward to working closely with our partner to make this treatment option available to patients and support better diabetes care across the country.”
The semaglutide injectable market in Brazil is approximately USD 413 million (IQVIA, MAT June 2026).
According to IQVIA MAT June 2026 data, the semaglutide injectable market in Brazil is valued at approximately USD 413 million, offering a significant commercial opportunity for the company.